Data as of Oct 28, 2026.

vsCompare their flowsaskIQ about these two fundsAsk the committee about these two funds
Across categories

BOND vs XBI: Differences, Returns & Fees

Share
Share on XDownload as PDF

Over the year to Oct 28, 2026, BOND returned −1.4% to XBI's +41.2%, and XBI charges 0.35% to BOND's 0.54%.

askIQ about this page

askIQ about BOND and XBI

Net assets: $8.3bn on Jun 30, 2026 for PIMCO Active Bond Exchange-Traded Fund, and $10.3bn on Oct 27, 2026 for State Street SPDR S&P Biotech ETF.

At a glance
−1.4%
BOND total return, 1 year
+41.2%
XBI total return, 1 year
0.54%
BOND expense ratio
0.35%
XBI expense ratio

Pair scorecard

XBI costs 0.19 points a year less; their one-year returns differ by 42.6 points.

BOND vs XBI: Differences, Returns & Fees
MeasureBONDXBI
Return
Total return, 1 year−1.4%+41.2%
Drawdown
Below its high3.1%, high on Feb 27, 2026
Below its all-time high8.9%, high on Feb 8, 2021
Benchmark
What it tracksNo index, actively managedBiotech
Cost and size
Expense ratio0.54%0.35%
Net assets, BOND as of Jun 30, 2026 and XBI as of Oct 27, 2026$8.3bn$10.3bn
Active share vs the S&P 50098%
Holdings
Holdings in common0%
In the S&P 500, by weight13%
Top ten holdings, share of the fund18%

Holdings in common uses holdings dated Jun 30, 2026 and Oct 27, 2026. Method

What they share

0%

By the books each fund has filed, BOND and XBI hold 0% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Oct 27, 2026.

0 half 100%

half

0% in common

Positions both hold · largest shared weight first BOND XBI
Only in one fund ↓
Only in BOND
UMBS, TBA 5.56%
PIMCO Mortgage-Backed Securities Active Exchange-Traded Fund 4.07%
UMBS, TBA 3.46%
United States Treasury 3.40%
UMBS, TBA 2.73%
United States Treasury 2.57%
UMBS, TBA 2.54%
UMBS, TBA 2.27%
Only in XBI
MODERNA INC 2.24%
TWIST BIOSCIENCE CORP 1.86%
NATERA INC 1.82%
BIOGEN INC 1.75%
HALOZYME THERAPEUTICS INC 1.75%
UNITED THERAPEUTICS CORP 1.71%
AMGEN INC 1.68%
ABBVIE INC 1.67%
Check overlap with more funds →

Side by side

BOND PIMCO Active Bond Exchange-Traded Fund XBI State Street SPDR S&P Biotech ETF
Where it sits Bond ETF Thematic ETF
What it is Actively managed Biotech
Total return, 1 year −1.4% +41.2%
Its benchmark over the same days −1.4% (AGG) not measured
Gap to its benchmark 0.0 pts vs AGG not measured
Expense ratio 0.54% 0.35%
Holdings 1565 165
Net assets, BOND as of Jun 30, 2026 and XBI as of Oct 27, 2026 $8.3bn $10.3bn

BOND and XBI on the fields both publish, as of Oct 28, 2026. Source: ETFIQ.

Alert

XBI flows, by email on Sundays.

One-click unsubscribe. See Privacy.

About each fund
BOND

BOND is actively managed and tracks no index. Over the year to Oct 28, 2026 it returned −1.4% with distributions reinvested, against −1.4% for its benchmark, the Bloomberg U.S. Aggregate Index. The prospectus expense ratio is 0.54% a year. It sat 3.1% below its high of Feb 27, 2026 on Oct 28, 2026.

XBI

By weight, 13% of XBI's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 18% of the fund across 165 positions, as published by its issuer for Oct 27, 2026. Over the year to Oct 28, 2026 the fund returned +41.2% with distributions reinvested. It sits 8.9% below its all-time high of Feb 8, 2021.

Questions people ask

Are BOND and XBI in the same category?
BOND is a bond ETF and XBI is a thematic ETF, so they do different jobs. The table compares what both publish: return, cost and holdings.
Which returned more over the last year, BOND or XBI?
In the year to Oct 28, 2026, with distributions reinvested, BOND returned −1.4% and XBI +41.2%.
Which is cheaper, BOND or XBI?
XBI is cheaper, by 0.19 percentage points a year. That is about $19 on $10,000 held for a year. Fees come from each fund's prospectus.
Other comparisons
Cite this pageCitation, APA and Markdown

ETFIQ, BOND against XBI, data as of Oct 28, 2026. https://etfiq.com/compare/any/bond-vs-xbi

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.